» Articles » PMID: 33042812

Evaluation of P2X7 Receptor Function in Tumor Contexts Using RAAV Vector and Nanobodies (AAVnano)

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Oct 12
PMID 33042812
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Adenosine triphosphate (ATP) represents a danger signal that accumulates in injured tissues, in inflammatory sites, and in the tumor microenvironment. Extracellular ATP is known to signal through plasma membrane receptors of the P2Y and P2X families. Among the P2X receptors, P2X7 has attracted increasing interest in the field of inflammation as well as in cancer. P2X7 is expressed by immune cells and by most malignant tumor cells where it plays a crucial yet complex role that remains to be clarified. P2X7 activity has been associated with production and release of pro-inflammatory cytokines, modulation of the activity and survival of immune cells, and the stimulation of proliferation and migratory properties of tumor cells. Hence, P2X7 plays an intricate role in the tumor microenvironment combining beneficial and detrimental effects that need to be further investigated. For this, we developed a novel methodology termed AAVnano based on the use of Adeno-associated viral vectors (AAV) encoding nanobodies targeting P2X7. We discuss here the advantages of this tool to study the different functions of P2X7 in cancer and other pathophysiological contexts.

Citing Articles

Functional role of P2X7 purinergic receptor in cancer and cancer-related pain.

Xu Y, Xiang J, Lin S Purinergic Signal. 2024; .

PMID: 38771429 DOI: 10.1007/s11302-024-10019-w.


Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice.

Abad C, Demeules M, Guillou C, Gonde H, Zoubairi R, Tan Y J Nanobiotechnology. 2024; 22(1):27.

PMID: 38212782 PMC: 10785547. DOI: 10.1186/s12951-023-02285-4.


Animal Models for the Investigation of P2X7 Receptors.

Sluyter R, Adriouch S, Fuller S, Nicke A, Sophocleous R, Watson D Int J Mol Sci. 2023; 24(9).

PMID: 37175933 PMC: 10179175. DOI: 10.3390/ijms24098225.


Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.

Hambach J, Mann A, Bannas P, Koch-Nolte F Front Immunol. 2022; 13:1005800.

PMID: 36405759 PMC: 9668101. DOI: 10.3389/fimmu.2022.1005800.


Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models .

Demeules M, Scarpitta A, Hardet R, Gonde H, Abad C, Blandin M Front Immunol. 2022; 13:1012534.

PMID: 36341324 PMC: 9626963. DOI: 10.3389/fimmu.2022.1012534.


References
1.
Hattori F, Ohshima Y, Seki S, Tsukimoto M, Sato M, Takenouchi T . Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7. Eur J Pharmacol. 2012; 695(1-3):20-6. DOI: 10.1016/j.ejphar.2012.09.001. View

2.
Matute C, Torre I, Perez-Cerda F, Perez-Samartin A, Alberdi E, Etxebarria E . P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci. 2007; 27(35):9525-33. PMC: 6673129. DOI: 10.1523/JNEUROSCI.0579-07.2007. View

3.
Muyldermans S . Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013; 82:775-97. DOI: 10.1146/annurev-biochem-063011-092449. View

4.
Rissiek B, Haag F, Boyer O, Koch-Nolte F, Adriouch S . ADP-ribosylation of P2X7: a matter of life and death for regulatory T cells and natural killer T cells. Curr Top Microbiol Immunol. 2014; 384:107-26. DOI: 10.1007/82_2014_420. View

5.
Di Virgilio F, Dal Ben D, Sarti A, Giuliani A, Falzoni S . The P2X7 Receptor in Infection and Inflammation. Immunity. 2017; 47(1):15-31. DOI: 10.1016/j.immuni.2017.06.020. View